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ABSTRACT Intravenous (i.v.) minocycline is increasingly used to treat infections
caused by multidrug-resistant (MDR) Acinetobacter baumannii. Despite its being
approved nearly 50 years ago, published information on its pharmacokinetic (PK)
profile is limited. This multicenter study examined the PK and probability of
pharmacokinetic-pharmacodynamic (PK-PD) target attainment profile of i.v. mino-
cycline in critically ill patients, with suspected or documented infection with
Gram-negative bacteria. The PK study population included 55 patients who re-
ceived a single 200-mg i.v. dose of minocycline. Plasma PK samples were col-
lected predose and 1, 4, 12, 24, 36, and 48 h after initiation of minocycline. Total
and unbound minocycline concentrations were determined at each time point.
Probabilities of achieving the PK-PD targets associated with stasis and 1-log
killing (free area under the curve above the MIC [fAUC:MIC] of 12 and 18, respec-
tively) in an immunocompetent animal pneumonia infection model of A. bau-
mannii were evaluated. A two-compartment population PK model with zero-
order i.v. input and first-order elimination, which estimated a constant fraction
unbound (fub) for minocycline, best characterized the total and unbound plasma
minocycline concentration-time data. The only two covariates retained in the fi-
nal PK model were body surface area (associated with central volume of distribu-
tion) and albumin (associated with fub). In the PK-PD probability of target attain-
ment analyses, minocycline 200 mg i.v. every 12 h (Q12H) was predicted to
result in a suboptimal PK-PD profile for patients with A. baumannii infections
with MIC values of 1 mg/liter. Like all PK-PD profiling studies of this nature,
these findings need clinical confirmation.
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Acinetobacter baumannii is a major cause of health care-associated infections incritically ill patients throughout the world. In recent years, a spike has occurred in
the prevalence of multidrug-resistant (MDR) A. baumannii infections, and carbapenem-
resistant Acinetobacter is now classified as an urgent public health threat pathogen by
the CDC (1–3). Few clinically effective antimicrobials are currently available to treat MDR
A. baumannii infections. The shortage of reliable agents has led clinicians to use
classical agents like minocycline for the treatment of MDR A. baumannii infections (4–6).
Minocycline is a semisynthetic derivative of tetracycline, has a broad spectrum of
activity against Gram-positive and Gram-negative bacteria, and is approved by the FDA
for the treatment of infections caused by Acinetobacter spp. (7, 8). Minocycline evades
most tetracycline resistance mechanisms and exhibits excellent in vitro microbiologic
activity against multidrug-resistant (MDR) Acinetobacter baumannii (1, 9, 10). To facili-
tate its use, a new formulation of minocycline (Minocin for Injection) was approved by
the U.S. Food and Drug Administration (FDA) in 2015, enabling minocycline to be
administered in 100 ml of normal saline over 1 h.
Although minocycline was approved nearly 50 years ago, surprisingly little is known
of its pharmacokinetic (PK) and pharmacokinetic-pharmacodynamic (PK-PD) target
attainment profile against A. baumannii. Most published PK data for intravenous (i.v.)
minocycline are from healthy participant studies conducted in the 1970s that used
bioassay quantification techniques (8, 11). The PK of minocycline has not been fully
characterized in patients with creatinine clearance (CLCR) of 80 ml/min (11), and the
FDA product labeling indicates that current data are insufficient to determine if dose
adjustments are warranted among patients with renal impairment (8). More impor-
tantly, it is unclear if current FDA dosing of i.v. minocycline is sufficient in achieving the
critical free plasma PK-PD exposure targets associated with bacterial killing in the lung
(12), especially among critically ill patients across the range of MIC values observed in
Acinetobacter sp. encountered in clinical practice.
Given these critical gaps in the literature, this study was conducted to examine the
PK of the currently marketed formulation of i.v. minocycline in critically ill patients with
suspected or documented Gram-negative infections in the intensive care unit (ICU).
Data obtained from this study were used to develop a population PK model to describe
the PK profile of minocycline in ICU patients and to examine potential patient factors
which may affect minocycline PK parameters. Monte Carlo simulations were performed
with the final PK model to evaluate the PK-PD target attainment profile of i.v. mino-
cycline against A. baumannii and to assess whether adjustments in the approved FDA
minocycline dosing regimen are needed for critically ill adults based upon clinically
relevant covariate effects.
RESULTS
Study population. Disposition of study population is shown in Fig. S1 in the
supplemental material. A total of 65 subjects were screened, and 58 were enrolled in
the study. Out of the 58 subjects enrolled, 57 subjects (98%) received the full dose of
the study product, 55 had at least 1 PK sample that was processed in accordance with
specified study procedures, 52 subjects (90%) completed follow-up, 50 subjects (86%)
were considered to be PK evaluable, and 49 subjects (84%) completed all PK blood
draws. In the safety population, no treatment-related Serious Adverse Events (SAEs)
were reported. One severe SAE (cardiopulmonary arrest resulting in death) was re-
ported but considered unrelated to the study product. Changes in laboratory values
and vital signs occurred over the 48-h observation period but were consistent with the
typical variability observed in these parameters among critically ill patients.
A total of 308 unbound and 310 total plasma minocycline concentrations collected
from 55 ICU patients were available for developing the population PK model. Since only
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2 unbound plasma minocycline concentrations were below the lower limit of quanti-
tation, these observations were excluded from the population PK analysis rather than
implementing the likelihood-based Beal M3 method (13).
Summary statistics of baseline patient characteristics for the PK analysis population
are presented in Table 1. The PK population was 54.5% male and 60.0% Caucasian. The
mean (SD) age was 61.7 (15.1) years and ranged from 23 to 89 years, body weight was
93.3 (33.3) kg and ranged from 44.1 to 246 kg, CLCR was 104 (61.4) ml/min/1.73 m2 and
ranged from 12.5 to 380 ml/min/1.73 m2, and albumin was 2.29 (0.618) g/liter and
ranged from 1 to 3.6 g/liter. Four subjects had measured serum creatinine (SCR) less
than 0.5 mg/dl, and for these individuals a capped value of 0.5 mg/dl was used in the
computation of CLCR to prevent derivation of nonphysiological CLCR values. Of the 10
patients who received renal replacement therapy (RRT), 9 received intermittent hemo-
dialysis (IHD) and 1 received continuous venovenous hemodialysis (CVVHD) at least
once during the PK sampling period.
Summary of total and unbound plasma minocycline concentrations. The mean 
SD of the observed total and unbound plasma minocycline concentration-time data are
presented on a linear (Fig. 1A) and semilog (Fig. 1B) scale. Visual inspection of these
plots indicated that both total and unbound minocycline concentrations declined in
parallel and in a biphasic fashion following the end of the approximately 1-h i.v.
infusion. A plot of the fraction of minocycline bound versus total minocycline concen-
tration using time-matched data, including a focus on only those total minocycline
concentrations less than 2 mg/liter, also demonstrated that the fraction unbound
appeared to remain constant and independent of total minocycline concentration
(Fig. 2).
Population structural PK model selection. During structural PK model develop-
ment, several variations of the two-compartment model were evaluated (Table S1). The
best structural PK model assumed that unbound minocycline concentrations were a
constant fraction of the total minocycline concentrations, that both total and unbound
minocycline concentrations could be cleared via IHD, and that no statistically significant
TABLE 1 Summary statistics of baseline patient demographic, clinical laboratory, and
disease-related characteristics for patients used to develop the population PK model
Variable n (%) Mean SD Median Min Max
Age (yr) 55 61.7 15.1 63.0 23 89
Wt (kg) 55 93.3 33.3 87.4 44.1 246
Ht (cm) 55 173 9.13 173 155 188
Body mass index (kg/m2) 55 31.2 10.6 30.4 16.5 77.9
Body surface area (m2) 55 2.11 0.38 2.08 1.42 3.57
Serum creatinine (SCR) (mg/dl)—all patients 55 2.20 2.42 1.19 0.3 13.1
SCR (mg/dl)—non-RRT patients 45 1.47 1.34 0.93 0.3 6.5
Albumin (g/liter) 55 2.29 0.62 2.40 1.0 3.6
Creatinine clearance (CLCR) (ml/min/1.73 m2)—all
patients
55 104 61.4 97.8 12.5 380
CLCR (ml/min/1.73 m2)—non-RRT patients 45 102 63.2 86.5 21.2 380
Sex, male 30 (54.5)
Race
Caucasian 33 (60.0)
Black or African American 21 (38.2)
Other 1 (1.82)
Ethnicity, non-Hispanic 54 (98.2)
Diabetes 23 (41.8)
Pulmonary hypertension 5 (9.09)
Renal failure 18 (32.7)
Heart failure 9 (16.4)
Hepatic failure 6 (10.9)
Receipt of vasopressorsa 19 (34.5)
aReceived any one of the following within 24 h of start of infusion until 26 h after the start of infusion:
norepinephrine, epinephrine, vasopressin, dopamine, phenylephrine, and dobutamine.
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differences existed between venous PK samples and the small number of arterial PK
samples (n  12) collected from three patients (including the one undergoing CVVHD).
The final parameter estimates for this model are provided in Table 2. All structural PK
model parameters were generally estimated with acceptable precision (standard error
of the mean [SEM] of 50%), including the estimate of the CLIHD parameter. The
two-compartment model provided an unbiased and excellent fit overall to the data.
Agreement between the observed and both the population predicted and individual
post hoc predicted and total plasma minocycline concentrations was excellent (r2 
0.61 and r2  0.99, respectively). Similar agreement between the observed and both
the population predicted and individual post hoc predicted unbound plasma minocy-
cline concentrations was also seen (r2  0.58 and r2  0.96, respectively).
Final PK model selection after covariate analysis. Plots of the individual post hoc
parameter minus the population mean parameter versus patient covariates using the
FIG 1 Mean  SD of the observed total and unbound plasma minocycline concentration-time data
following a single i.v. infusion of 200 mg minocycline over 1 h to critically ill patients, presented on a
linear (A) and semilog (B) scale. Red lines are total minocycline concentrations, and black lines are
unbound minocycline concentrations.
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base structural population PK model are provided in Appendix B in the supplemental
material. Based upon this graphical screening procedure, only selected patient covariate-
parameter relationships were formally tested within NONMEM as summarized in Appendix
C in the supplemental material. In step 1 of forward selection of patient covariates, the
effect of albumin on fub, when parameterized as a decreasing power function, was the most
statistically significant parameter-covariate relationship (P  0.00010) and was added to
form a new base structural PK model. This covariate effect reduced the magnitude of 2 for
fub from 31.3% coefficient of variation (CV) to 27.0% CV. In step 2, the effect of body surface
area (BSA) on central volume of distribution (Vc), when parameterized as an increasing
power function, was the most statistically significant parameter-covariate relationship
(P  0.00374) and was added to the model. This covariate effect reduced the magnitude of
2 for Vc from 55.1% CV to 50.6% CV. No additional covariates were added to the model
in step 3.
FIG 2 Plot of fraction of minocycline bound versus total minocycline concentration using time-matched
data from critically ill patients using all available data (A) and with focus on only those total minocycline
concentrations less than 2 mg/liter (B). Green line and grey shaded region represent Loess smooth spline
and 90% confidence interval.
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A scatterplot matrix of interindividual error terms (ETAs) indicated that the covari-
ances between CL and Vc, fub and Vc, and fub and Vp were the strongest and
were considered part of the full multivariable PK model. The covariances between CL
and Vc and between fub and Vp were successfully estimated in the full multivariable
model and significantly reduced the NONMEM minimum value of the objective func-
tion (MVOF) (decrease of 20.187 with 2 df, P  0.00004). Covariance terms involving Vc
were not included in the full multivariable model as they did not significantly lower the
NONMEM MVOF and led to many covariance terms estimated with poor precision.
Histograms of the ETAs for each structural PK model parameter were symmetrical and
did not appear to deviate from normality.
During stepwise backward elimination, all of the covariate effects remaining in the
model remained statistically significant at the more stringent   0.001. The only
exception was that the effect of BSA on Vc was marginally not statistically significant
(P  0.00145), which is in part due to the small number of subjects in this study.
However, this covariate effect was retained in the population PK model given the
theoretical importance of body size in volume of distribution and the fact that the
magnitude of 2 for Vc increased substantially when this covariate effect was removed.
The final parameter estimates for the final two-compartment population PK model
are provided in Table 2. All population PK model parameters were estimated with
acceptable precision (SEM  50%), including the estimate of the CLIHD parameter. The
population mean CL for total minocycline was estimated to be 4.70 liters/h, and the
steady-state volume of distribution (Vc  Vp) was 133 liters. The total minocycline CLIHD
was estimated to be 5.55 liters/h, which was quantitatively similar to the total mino-
cycline CL. The fub was estimated to be 0.280; the unbound minocycline CL was
calculated to be 1.32 liters/h. The mean  SD half-lives at  phase and  phase (T1/2,
and T1/2,, respectively) calculated using the individual post hoc parameters were
1.36  0.456 h and 23.4  9.53 h, respectively. The magnitude of 2 was 45.6% CV for
CL, 49.9% CV for Vc, 34.1% CV for Vp, and 27.1% CV for fub. The residual variability was
TABLE 2 Parameter estimates and associated standard errors for the base and final two-
compartment population PK model with constant fraction unbounda
Parameter
Base model Final modelb
Final estimate %SEM Final estimate %SEM
CL (liters/h) 4.68 6.22 4.70 6.24
Vc (liters) at median BSA of 2.08 m2 74.2 8.12 74.5 6.60
Vc-BSA power 1.21 30.1
CLd (liters/h) 16.2 8.66 16.0 8.66
Vp (liters) 58.6 5.81 58.9 5.89
fub at median albumin of 2.40 g/dl 0.293 4.45 0.280 3.53
fub-albumin power 0.533 23.2
CLIHD (liters/h)c 5.57 46.7 5.55 46.8
2 for CL 0.209 (45.8% CV) 17.9 0.208 (45.6% CV) 18.1
2 for Vc 0.305 (55.2% CV) 31.0 0.250 (49.9% CV) 38.0
2 for Vp 0.111 (33.3% CV) 31.2 0.117 (34.1% CV) 30.7
2 for fub 0.0979 (31.3% CV) 32.3 0.0733 (27.1% CV) 35.4
Covariance (CL, Vc) 0.101 (r2  0.196) 34.5
Covariance (fub, Vp) 0.0478 (r2  0.266) 42.7
Residual variability (2)
Total minocycline 0.00832 (9.12% CV) 17.0 0.00843 (9.18% CV) 15.6
Unbound minocycline 0.0252 (15.9% CV) 18.3 0.0251 (15.8% CV) 17.6
aBSA, body surface area; CL, clearance; Vc, central volume of distribution; CLd, distribution clearance; Vp,
peripheral volume of distribution; fub, fraction unbound; CLIHD, clearance related to active intermittent
hemodialysis; SEM, standard error of the mean.
bEta-shrinkage was 3.16% for CL, Vc, and fub while it was only 14.9% for Vp.
cEffective only during periods where intermittent hemodialysis was performed. 2 on CLd was negligible and
fixed to zero in the model.
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9.18% CV and 15.8% for total and unbound minocycline, respectively. Summary statis-
tics of individual post hoc PK parameters and calculated exposures for total and
unbound minocycline in ICU patients using the final two-compartment population PK
model are provided in Table 3.
The final two-compartment population PK model with constant fub provided an
unbiased and excellent fit overall to the data (Fig. 3 and 4). Agreement between the
observed and both the population predicted and individual post hoc predicted total
(r2  0.66 and r2  0.99, respectively) and unbound (r2  0.67 and r2  0.96,
respectively) plasma minocycline concentrations was excellent. Plots of the observed
and individual post hoc predictions of total and unbound plasma minocycline for each
patient further demonstrate the accuracy and precision of the PK model (Fig. S2); it can
be seen that only one patient had comparable total and unbound minocycline con-
centrations, which could indicate assay error (fub was estimated to be 0.95 for this
patient). The addition of albumin and BSA as covariates on fub and Vc, respectively,
contributed to the improvement in the population mean predictions. Histograms of
normalized prediction distribution errors (NPDE) for the fit of the final two-
compartment population PK model (Fig. S3) were symmetrical around a mean value of
zero and appeared to be normally distributed as would be expected if the fixed and
random effects were specified correctly. Lastly, visual predictive checks for the fit of the
final population model to the total and unbound plasma minocycline concentration-
time data from ICU patients demonstrated excellent agreement between the median
and 90% prediction interval of the observed and simulated unbound and total mino-
cycline concentration-time data (Fig. 5), confirming the adequacy of the population PK
model both for characterizing the existing data and for the purposes of performing
simulations.
Pharmacokinetic-pharmacodynamic target attainment assessment. Results of
the probability of free-drug plasma PK-PD target attainment analyses for i.v. minocy-
cline 200 mg administered every 12 h (Q12H) under steady-state conditions are shown
in Fig. 6. The probability of achieving the fAUC:MIC (free area under the curve above the
MIC) target of 12 in plasma for net bacterial stasis was 90% of simulated patients for
A. baumannii isolates with MIC values of 1 mg/liter. The probability of achieving the
fAUC:MIC target of 18 in plasma for 1-log change in log10CFU was 90% of simulated
patients for A. baumannii infections with MIC values of 0.5 mg/liter.
DISCUSSION
This multicenter study was performed to evaluate the time course of both unbound
and total plasma minocycline concentrations in critically ill patients using modern
bioanalytical methods. Overall, the PK of i.v. minocycline in critically ill patients aligned
with the data from PK studies in older healthy participants (6, 8, 11). Consistent with
other tetracyclines, a two-compartment population PK model with zero-order i.v. input
TABLE 3 Summary statistics of individual post hoc PK parameters and calculated
exposures for total and unbound minocycline in ICU patients using the final two-
compartment population PK model with constant fraction unbound for minocycline
Variable n Mean SD Median Min Max
Total Cmax (mg/liter) 55 2.58 1.33 2.24 0.539 7.88
Unbound Cmax (mg/liter) 55 0.749 0.364 0.629 0.238 2.21
Tmax (h) 55 1.02 0.0848 1.00 0.750 1.48
Total AUC0–24 (mg · h/liter) 55 24.3 7.88 22.8 8.09 50.9
Total AUC0–∞ (mg · h/liter) 55 46.6 19.7 44.4 15.1 96.7
Unbound AUC0–24 (mg · h/liter) 55 7.18 2.46 7.12 2.74 13.3
Unbound AUC0–∞ (mg · h/liter) 55 14.1 6.68 13.7 3.65 29.2
CL (liters/h) 55 5.24 2.63 4.50 2.07 13.2
Vss (liters) 55 146 57.0 140 54.7 465
T1/2, (h) 55 1.36 0.456 1.35 0.448 3.44
T1/2, (h) 55 23.4 9.53 20.3 8.87 46.8
fub 55 0.309 0.120 0.280 0.159 0.957
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and first-order elimination with a constant fub best characterized the total plasma
minocycline concentration-time data from critically ill patients (14). The median of the
individual post hoc T1/2, values from these critically ill patients was 20.3 h and fell
within the previously reported range of elimination half-life values of 15 to 23 h (6, 8,
11, 15). The median volume of distribution at steady state (Vss) and CL observed in
ACUMIN were slightly higher than previous reports, but this was likely a function of the
greater variability around PK exposure estimates (e.g., Vss and CL) in critically ill patients
FIG 3 Goodness-of-fit plots for the fit of the final two-compartment population PK model with constant fraction unbound to the total
plasma minocycline concentration-time data from critically ill patients.
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relative to studies of healthy participants, and this speaks directly to the differing
physiological states across patients in the ICU.
The findings do not support the current paradigm that tetracyclines exhibit inverse
nonlinear protein binding across the range of minocycline concentrations observed in
this study (0.05 to ~4 mg/liter as shown in Fig. 2) (16), which had been proposed based
on protein binding estimates derived from in vitro and animal studies (17). A distin-
guishing feature of this study was the determination of both total and unbound
minocycline concentrations at each PK collection time point. The ability to comodel
both unbound and total minocycline concentrations allows for direct estimation of the
FIG 4 Goodness-of-fit plots for the fit of the final two-compartment population PK model with constant fraction unbound to the
unbound plasma minocycline concentration-time data from critically ill patients.
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fraction of unbound drug at any given time and for evaluation of whether this fraction was
constant or a function of total minocycline concentration. In the current analysis, a two-
compartment population PK model with an estimated constant fub for minocycline enabled
simultaneous characterization of the time-matched total and unbound plasma minocycline
concentration-time data collected in this study. Other structural models with nonlinear
protein binding were considered but none improved model fit (see Table S1 in the
supplemental material). Selection of a two-compartment population PK model with an
estimated constant fub is further supported by a plot of the bound versus total
minocycline concentrations using the observed time-matched PK data, which clearly
demonstrate that fub is independent of the total minocycline concentration. Finally, the
total and unbound minocycline concentration-time curves within each patient are
parallel to each other, supporting that fub is constant and not related to the observed
total concentration.
The finding that fub for minocycline was constant is consistent with the current
understanding of the rapid equilibrium assumption between protein-bound and un-
bound drug (18–20). In short, the protein-bound fraction of drug appears to act as a
FIG 5 Visual predictive check for the fit of the final two-compartment population PK model with constant
fraction unbound to the total and unbound plasma minocycline concentration-time data from critically
ill patients. Red (simulated) and blue (observed) indicate median and 90% prediction interval; black dots
are observed data.
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reservoir within the central compartment as it is expected that only unbound drug is
distributed to tissues and/or eliminated from the body. As unbound drug distributes to
tissues and/or is eliminated from the body, bound drug rapidly dissociates from
albumin and other circulating proteins. This rapid dissociation preserves the equilibra-
tion between bound and unbound drug and results in proportional distribution and
clearance terms between the bound and unbound fraction of drugs. If rapid equilibra-
tion did not occur, the PK profiles for total and unbound minocycline concentrations in
plasma would not have declined in parallel, as was observed in this study, and PK
models with nonlinear protein binding would have fit our data more closely.
The findings also demonstrate a lack of association between CL and CLCR. This
finding was not surprising given that CLCR was found to contribute only 11% to the
total CL in previous studies of subjects with normal renal function in which urinary
excretion of minocycline was measured (6, 11). However, this finding is clinically
important, confirming no need for minocycline dosage adjustments in patients with
renal impairment. Although patients on RRT were included in the study population, this
study was not designed to evaluate the impact of RRT on the PK of minocycline.
Consistent with other PK studies in critically ill patients that include patients on RRT
(39), our methodology determined if plasma clearance was augmented in patients on
IHD. The minocycline concentrations observed in IHD patients indicates that there was
some increased clearance during the times that IHD was administered.
The two covariates retained in the final population PK model (BSA associated with
FIG 6 Percentage of simulated patients achieving the fAUC:MIC plasma targets of either 12 (net bacterial
stasis) or 18 (1-log10CFU kill) for the 200 mg i.v. Q12H minocycline dosing regimen at steady state
conditions against (A) A. baumannii-A. calcoaceticus complex and (B) multidrug resistant (MDR) A.
baumannii-A. calcoaceticus complex (7).
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Vc and albumin associated with fub) were not unexpected and are biologically plausible.
The volume of distribution of many drugs increases with body size, and circulating
plasma proteins like albumin can directly contribute to reducing the free fraction of
many drugs. While studies suggest that systemic exposures are reduced in patients
with hypoalbuminemia due to increases in Vss and CL secondary to increased fub (21),
we did not find this to be the case for minocycline, as CL was found to be independent
of albumin.
We do not anticipate that BSA differences across critically ill patients will have any
bearing on achieving critical PK-PD targets since changes in Vc do not affect the AUC.
However, the association between fub and albumin may have implications for clinical
practice for critically ill patients as the extent of unbound drug is driven, in part, by fub.
The observed albumin concentrations in the ACUMIN study ranged from 1.0 to 3.6 g/dl
(normal range for albumin in healthy subjects is typically 3.4 to 5.4 g/dl). The model
predicted fub varying from 0.446 to 0.236 over the range of 1 g/dl to 3.4 g/dl (Fig. 7).
Although fub appears to flatten at higher albumin concentrations, the model predicts
that fub would decrease to 0.182 for patients with albumin levels at the upper range of
normal (5.4 g/dl). Of note, the model-predicted range of fub for subjects with normal
albumin concentrations (0.182 to 0.236) would be qualitatively similar to values previ-
ously reported for minocycline of 24% (11). Given the predicted increase in fub over the
albumin range of 1 g/dl to 3.6 g/dl, the probability of PK-PD target attainment profile
may be less robust among individuals with albumin levels in the normal range than among
those with extremely low albumin concentrations. However, the model predicts that a
doubling in the fub will shift the probability of target attainment profile downward, at most,
by only 1 MIC doubling dilution, assuming there are no corresponding changes in CL (21).
It is important to note that the low albumin levels observed in ACUMIN do not
mitigate the external generalizability of the findings. Hypoalbuminemia is common-
place in critically ill patients, with reported incidences as high as 40 to 50% (22).
However, the findings from ACUMIN should be applied only to critically ill patients with
similarly low albumin concentrations. Studies suggest that systemic exposures are
reduced in patients with hypoalbuminemia due to increases in Vss and CL secondary to
increased fub (21). Although we did observe an association between CL and albumin,
the extent of protein binding observed in the ACUMIN study population may have
contributed to the faster CL values reported in this study relative to historical values.
FIG 7 Model-predicted typical value of the fraction of minocycline bound (fub) versus albumin concen-
tration, overlaid upon the individual post hoc fub values obtained using the final population PK model
characterizing the total and unbound plasma minocycline concentration-time data from critically ill
patients.
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Further PK data are needed to clarify the effect of albumin on fub for minocycline in
patients with normal albumin, and extrapolation of our findings to patients with normal
albumin concentrations should be done with caution.
Lastly, the findings from the probability of ƒAUC:MIC in plasma target attainment
analyses suggest that the current i.v. minocycline dosing employed in clinical practice
confers a suboptimal (90%) probability of microbiologic efficacy in plasma for a
proportion of critically ill patients with A. baumannii infections. Minocycline 200 mg i.v.
Q12H, the maximum daily dosing regimen recommended in the product labeling, only
achieved the critical ƒAUC:MIC targets in plasma associated with stasis and 1-log
killing for A. baumannii isolates with MIC values of 1 mg/liter. In a recent U.S.
surveillance MIC study consisting of 1,081 clinical isolates of A. baumannii-A. calcoace-
ticus complex by Flamm et al. (7), 31.3% of isolates had a MIC value of 1 mg/liter.
Among MDR A. baumannii-A. calcoaceticus complex, the minocycline MIC value was 1
mg/liter for 60% of the tested isolates (Fig. 6). Assuming fub remains constant at
concentrations higher than that observed in this study, a 1,600-mg i.v. Q12H minocy-
cline dosing regimen would be required to ensure 90% probability of achieving the
ƒAUC:MIC target associated with stasis in plasma for A. baumannii isolates up to the
MIC90 (e.g., MIC of 8 mg/liter) that was observed in the surveillance study by Flamm
and colleagues (7). As fub may not remain constant at concentrations higher than that
observed in our study, our simulation result of the 1,600 mg i.v. Q12H dosing regimen
should be interpreted with caution. While i.v. minocycline daily doses of 400 mg
appear safe in acute stroke/actual spinal cord injury patients (23, 24), little to no
information exists with daily doses of i.v. minocycline in excess of 400 mg in critically
ill patients with infections. In a recent phase 1 study of healthy adult subjects, single i.v.
doses of minocycline up to 600 mg were well tolerated, and the maximum tolerated
multidose was 300 mg i.v. twice daily (40). Thus, higher i.v. minocycline daily doses like
those used in acute stroke/actual spinal cord injury patients and healthy subjects
cannot be endorsed at this time in critically ill patients with infections. Use of higher i.v.
minocycline doses in critically ill patients with infections requires a detailed risk-versus-
benefit assessment as many of the toxicities associated with minocycline, like azotemia,
hyperphosphatemia, acidosis, and other metabolic disturbances, are related to the
extent of systemic exposure (8).
Like all studies of this nature, a certain degree of caution should be exercised in
interpreting the findings from the probability of ƒAUC:MIC plasma target attainment
analyses. The ƒAUC:MIC targets in plasma utilized were derived from a preclinical PK-PD
infection model (12), and no clinical exposure-response studies are available to judge
the adequacy of current dosing. Preclinical PK-PD infection model studies are an
integral part of the drug development process and are used to inform dose and
schedule selection, especially for the treatment of highly resistant bacterial pathogens
when limited clinical data are available to define optimal therapy (25–27). Furthermore,
the plasma PK-PD targets utilized were obtained from an immunocompetent rat
pneumonia infection model of A. baumannii and, accordingly, likely reflect the
ƒAUC:MIC targets in plasma required for bacterial killing in the lung (12). It is well
established that minocycline achieves greater concentrations in the lungs than in
plasma (28, 29). Although the concentrations of minocycline were not assayed in the
epithelial lining fluid (ELF) in the immunocompetent rat pneumonia infection model of
A. baumannii study, it is reasonable to surmise that these ƒAUC:MIC plasma targets are
reflective of the higher concentrations achieved in the ELF (i.e., site of infection) that are
needed for bacterial killing in the lung. Based on the probability of achieving the
ƒAUC:MIC plasma targets derived in an immunocompetent rat pneumonia infection
model of A. baumannii, combination antibiotic therapy should be potentially consid-
ered in patients with Acinetobacter sp. infections, especially MDR strains. Given that the
probability of attainment analyses were based on ƒAUC:MIC plasma targets from an
animal model, there is also the need for clinical validation (30).
In summary, a two-compartment population PK model with zero-order i.v. input and
first-order elimination, with an estimated constant fub, best characterized the total and
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unbound plasma minocycline concentration-time data in critically ill patients. In the
ƒAUC:MIC plasma target attainment analyses using the final population PK model, the
200-mg i.v. Q12H minocycline dosing regimen currently employed in clinical practice
was predicted to result in a suboptimal ƒAUC:MIC profile in plasma for nearly a third of
patients with A. baumannii infections, and daily doses of 400 mg a day would be
needed to adequately cover A. baumannii infections with MIC values of 1 mg/liter.
Although i.v. minocycline was found to be safe in this single i.v. dose PK study in
critically ill patients, clinicians need to conduct a detailed risk-versus-benefit assess-
ment when contemplating the use of higher minocycline doses for their patients. Like
all PK-PD profiling studies of this nature, these findings need clinical confirmation.
Clinicians should potentially consider using combination antibiotic therapy when using
i.v. minocycline in patients with Acinetobacter sp. infections, especially those caused by
MDR strains, based on the findings from the probability of target attainment analyses.
The findings from the study also suggest that the current minocycline FDA suscepti-
bility breakpoint of 4 mg/liter should perhaps be revisited in future clinical investi-
gations to validate the probability of target analyses, which were based on ƒAUC:MIC
plasma targets derived in a rat pneumonia model of A. baumannii.
MATERIALS AND METHODS
Study design and treatment administration. The ACUMIN Study (ClinicalTrials.gov identifier
NCT03369951) was a phase IV, multicenter, open-label multicenter study to evaluate the PK of a single
dose of i.v. minocycline in up to 50 evaluable, ICU patients already receiving antimicrobial therapy for a
known or suspected Gram-negative infection (31). Study criteria and the definition of the PK evaluable
population are listed in Appendix A in the supplemental material. Institutional review board approval
was obtained at each participating center. Once patients were confirmed as eligible, and informed
consent was obtained, patients were enrolled into the study. Each subject received a single 200 mg i.v.
infusion of minocycline in 100 ml of normal saline administered at a rate of 100 ml/h until the bag was
empty and the line was flushed. Safety assessments performed are included in Appendix A in the
supplemental material.
Pharmacokinetic sample collection. Blood samples (6 ml) to assess the PK of minocycline were
collected over a 48-h period after treatment administration, preferably from the arm contralateral to the
one used for i.v. infusion. Blood samples were collected predose, immediately after infusion termination
(1 h), and at 4, 12, 24, 36, and 48 h after treatment administration. For each PK blood sample, plasma
was separated into 2 aliquots. One plasma aliquot was used for determination of total minocycline. For
the other plasma aliquot, centrifugation was used to generation ultrafiltered plasma for determination
of unbound minocycline. Both aliquots were stored frozen until being shipped to the central laboratory
for testing. Methods for the determination of minocycline in human EDTA K2 plasma were validated at
the Syneos Health bioanalytical lab (Quebec, Canada). The total plasma PK samples were used to analyze
total minocycline concentrations, and the ultrafiltered plasma was used to determine unbound mino-
cycline. Plasma PK samples were analyzed for both unbound and total minocycline concentrations using
liquid chromatography-tandem mass spectrometry (LC-MS/MS) (AB Sciex API 5000 equipped with an
electrospray).
LC-MS/MS methods for the determination of total minocycline. The samples with minocycline
and the internal standard (IS) (Minocycline-d6) are cleaned by liquid-liquid extraction using ethyl acetate.
After vortex and centrifugation, 50 	l of the organic phase is transferred by the liquid handling system
in a 96-well plate. Samples are then evaporated and reconstituted with 200 	l of a methanol-water
solution. A 15-	l sample is injected into the LC-MS/MS system for analysis. The LC-MS/MS analyses were
carried out with an AB Sciex API 5000 equipped with a turbo ion spray source operated in the positive
ionization mode. Chromatographic separation was carried out on a Life Sciences Ace 3-C18 column
(50 mm by 4.6 mm, 3 	m). The MS operating conditions were optimized as follows. The ion spray voltage
was set at 4,000, and the source temperature was maintained at 500°C. The collision energy was set at
25. Quantification was obtained by using multiple reaction monitoring (MRM) mode of the transitions at
m/z 458.4 ¡ 441.2 for minocycline and at m/z 464.3 ¡ 447.1 for IS, respectively. Data acquisition and
integration of multiple reaction monitoring chromatograms were performed using the software package
Analyst 1.6.3. (AB Sciex, Toronto, Canada). A linear regression (weighted 1/	2) was applied to a plot of
the peak area ratio versus concentration for the standards to obtain the calibration curve. The standard
curve range is 40 to 10,000 ng/ml. Interassay precision for quality controls (QCs) was as follows: biases,
4.85 to 0.39%; CV, 2.61 to 5.84%.
LC-MS/MS methods for the determination of unbound minocycline. The samples with unbound
minocycline and the internal standard (Minocycline-d6) are cleaned by liquid-liquid extraction using
ethyl acetate. After vortexing and centrifugation, 100 	l of the organic phase is transferred by the liquid
handling system in a 96-well plate. Samples are then evaporated and reconstituted with 200 	l of a
methanol-water solution. A 15-	l sample is injected into the LC-MS/MS system for analysis. The
LC-MS/MS analyses were carried out with an AB Sciex API 5000 equipped with a turbo ion spray source
operated in the positive ionization mode. Chromatographic separation was carried out on a Life Sciences
Ace 3-C18 column (50 mm by 4.6 mm, 3 	m). The MS operating conditions were optimized as follows. The
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ion spray voltage was set at 4,000, and the source temperature was maintained at 500°C. The collision
energy was set at 31. Quantification was obtained by using multiple reaction monitoring (MRM) mode
of the transitions at m/z 458.3 ¡ 441.0 for minocycline and at m/z 464.2 ¡ 447.1 for IS, respectively. Data
acquisition and integration of multiple reaction monitoring chromatograms were performed using the
software package Analyst 1.6.3. (AB Sciex, Toronto, Canada). A linear regression (weighted 1/	2) was
applied to a plot of the peak area ratio versus concentration for the standards to obtain the calibration
curve. The standard curve range is 20 to 3,000 ng/ml. Interassay precision for QCs was as follows: biases,
6.68 to 0.26%; CV, 3.22 to 5.38%.
Population PK analysis. (i) Structural PK model selection. The population PK analysis was
conducted using NONMEM version 7.3 (Icon Development Solutions, Ellicott City, MD) implementing the
first-order conditional estimation method with -
 interaction (FOCEI). Based on prior minocycline PK
modeling studies (11), a two-compartment model with zero-order input and first-order elimination to
simultaneously fit the total and unbound plasma minocycline concentration-time data was used as the
structural PK model. The two-compartment model was parameterized using total clearance (CL, in
liters/h), central volume of distribution (Vc, in liters), distribution clearance between the central and
peripheral compartment (CLd, in liters/h), and the volume of distribution for the peripheral compartment
(Vp, in liters). An additional CL term (CLIHD) was included to account for total minocycline removed during
periods of intermittent hemodialysis (IHD). Based upon exploratory graphical analyses of the total and
free minocycline concentration-time profiles, the fraction of minocycline unbound (fub) was assumed to
remain as a constant function of total minocycline concentration in order to comodel the unbound and
total minocycline concentration-time data. Unbound minocycline concentrations at any given time were
determined as the product of total minocycline concentrations and fub. Interindividual variability (2) was
estimated for CL, Vc, CLd, Vp, and fub using exponential error models. Separate combined additive plus
constant coefficient of variation (CCV) error models were used to describe residual variability (2) for the
unbound and total plasma minocycline concentrations.
Other structural PK models or modifications, such as inclusion of nonlinear plasma protein binding
as a function of total minocycline concentration (16, 17), were also considered to identify the most
parsimonious model which provided the best possible fit to the data. Saturable protein binding was
implemented using a quasiequilibrium binding model, similar in nature to a target-mediated drug
disposition model, in which the maximal binding capacity (Bmax, in milligrams/liter) and binding
dissociation constant (KD, in milligrams/liter) were estimated (32, 33). Using this approach, the fub would
not be constant and free minocycline concentrations would instead be a nonlinear function of the total
minocycline concentrations.
Population PK models were assessed by evaluating the individual and population mean PK param-
eter estimates for minocycline, and their precision as measured by the percent standard error of the
population mean estimate (%SEM), along with the ability to reduce the magnitude of the unexplained
2 and 2. Graphical examination of standard diagnostic and population analysis goodness-of-fit plots
was also considered, such as observed versus both population and individual post hoc predicted total
and unbound minocycline concentrations; conditional population weighted residuals versus time since
last dose, population predicted total and unbound minocycline concentrations, and potentially other
independent variables; individual weighted residuals versus individual post hoc predicted total and
unbound minocycline concentrations; and the agreement between the observed and individual post hoc
predicted plasma minocycline concentration-time data (individual observed and predicted overlays).
Lastly, a likelihood ratio test was used to assess the statistical significance of adding or deleting a
parameter from the model based upon differences in minimum value of the objective function
(MVOF) for nested models, and Akaike’s information criterion (AIC) was used to compare nonnested
models (34).
(ii) Final PK model selection after covariate analysis. After developing a base structural population
PK model to describe the unbound and total plasma minocycline concentrations, a formal covariate
analysis was performed using stepwise forward selection (  0.01) and backward elimination ( 
0.001) techniques as described in detail in Appendix A in the supplemental material. Patient demo-
graphic descriptors considered in the covariate analysis included sex, age in years, weight in kilograms,
height in centimeters, body surface area (BSA) in square meters (35), body mass index (BMI) in
kilograms/square meter, and ideal body weight (IBW) in kilograms. Clinical laboratory data utilized as
covariates included serum creatinine (SCR) in milligrams/deciliter, albumin in grams/deciliter, and calcu-
lated CLCR in milliliters/minute/1.73 m2 using the Cockcroft and Gault method and normalized to a BSA
of 1.73 m2 (36–38). Other disease-related indices such as the presence of diabetes, hepatic cirrhosis,
pulmonary hypertension, organ transplantation, renal failure, and lastly heart failure as well as the
corresponding New York Heart Association (NYHA) class were evaluated as patient covariates. Informa-
tion pertaining to receipt of any renal replacement therapy (RRT) were collected from 1 h after start of
infusion through 48 h after start of infusion. The approach used to account for RRT in the population PK
model was determined based upon the type of RRT utilized, the timing and duration of RRT relative to
dosing and PK sample collection, and potentially other more detailed information provided for each
patient. For patients on continuous RRT, the effluent dialysis rate was substituted for CLCR during
covariate evaluation.
The final population PK model after covariate analyses was assessed using the same model diagnostic
and evaluation criteria as described previously. Covariances between the interindividual variability (IIV)
terms were evaluated and estimated in the variance-covariance matrix for the final population PK model
if warranted. In addition, the overall distribution of the normalized prediction distribution errors (NPDE)
provided by NONMEM for the unbound and total plasma minocycline concentrations was evaluated and
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compared to a normal distribution to determine if the fixed or random effects models were biased. The
final population PK model was further evaluated and qualified by performing a visual predictive check
(VPC), which graphically examined the agreement between the 5th, 50th, and 95th percentiles of the
observed and the individual simulated unbound and total plasma minocycline concentrations across
time intervals.
(iii) Generation of individual pharmacokinetic parameters. The individual patient dosing histories
were utilized along with the individual post hoc PK parameters to generate unbound and total plasma
minocycline concentration-time profiles and calculate unbound and total plasma minocycline exposure
measures (maximum concentration of drug in plasma [Cmax], AUC0 –24, and AUC0 –∞). The Cmax was
calculated for each simulated patient as the maximum simulated concentration. The AUC0 –24 was
calculated using numerical integration using the data from 0 to 24 h postdose. The AUC0 –∞
was calculated as dose/CL. The steady-state volume of distribution (Vss  Vc  Vp), alpha-phase half-life
(T1/2,), and beta-phase half-life (T1/2,) were calculated using the individual post hoc PK parameters.
(iv) Pharmacokinetic-pharmacodynamic target attainment assessment. Using the final popula-
tion PK model including all statistically significant covariate effects, Monte Carlo simulation was per-
formed using R (via the MRGSOLVE package). Simulated total and unbound minocycline concentrations
for 2,000 virtual patients (non-IHD patients) were generated at steady state for the FDA-approved i.v.
minocycline dosing regimen of 200 mg administered every 12 h. Virtual patients were simulated from
normal distributions using the same mean (SD) BSA of 2.11 (0.38) and albumin of 2.29 (0.62) as was
observed in the ACUMIN study population. The percentage of simulated patients achieving an ƒAUC:MIC
target of either 12 or 18 during the 12-h dosing interval at steady-state was assessed over a range of MIC
values observed for A. baumannii. These free PK-PD targets in plasma were based on the results of a rat
lung pneumonia infection model, which demonstrated that bacterial stasis and 1-log change in log10CFU
in the lungs with minocycline against four different clinical isolates of A. baumannii (MICs ranged from
0.25 to 4 mg/liter) were achieved at fAUC:MIC ratios in plasma of 12 and 18, respectively (12). Recent
surveillance MIC data for A. baumannii-A. calcoaceticus complex and MDR baumannii-A. calcoaceticus
complex published by Flamm et al. were utilized in the PK-PD target attainment analysis (7).
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Researchers interested in accessing the clinical trial data presented here are encour-
aged to submit a research proposal and publication plan. The proposal and plan will be
reviewed by the ARLG publications committee and/or appropriate study team mem-
bers. If approved and upon receipt and approval of a signed data access/use agree-
ment, individual participant data necessary to complete the proposed analysis will
be made available. Related documents, including the study protocol, statistical
analysis plan, and data dictionary, may also be shared. Access to data will be
granted only to researchers who provide a methodologically and scientifically
sound proposal. Proposed analyses that are duplicative of ongoing or proposed
analyses may not be supported. To submit a proposal, please complete a proposal
at https://arlg.org/how-to-apply/protocol-concept. Alternatively, visit dcri.org/data-
sharing. There may be costs associated with data sharing that researchers would be
expected to cover.
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